# A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

> **NCT00551213** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 67 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Robatumumab
- **DRUG:** Irinotecan
- **BIOLOGICAL:** Cetuximab
- **DRUG:** Capecitabine
- **DRUG:** FOLFOX
- **DRUG:** CAPEOX/XELOX
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT00551213
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-21
- **Primary completion:** 2009-06-04
- **Final completion:** 2009-06-04
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2018-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551213, "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00551213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*